OB fusion protein compositions and methods

Details OB fusion protein compositions and methods OB fusion protein compositions and methods

2006-09-22

2011-12-20

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S193100, C424S194100, C424S185100, C514S003200, C514S005800, C514S057000, C514S059000, C530S350000, C530S389100, C530S399000

Reexamination Certificate

active

08080254

ABSTRACT:
The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5169318 (1992-12-01), Levy
patent: 5225538 (1993-07-01), Capon et al.
patent: 5284656 (1994-02-01), Platz et al.
patent: 5349053 (1994-09-01), Landolfi et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5594101 (1997-01-01), Becker et al.
patent: 5594104 (1997-01-01), Basinski et al.
patent: 5646040 (1997-07-01), Kleyn et al.
patent: 5670625 (1997-09-01), Baum et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5935810 (1999-08-01), Friedman et al.
patent: 6001968 (1999-12-01), Friedman et al.
patent: 6025325 (2000-02-01), Campfield et al.
patent: 6048837 (2000-04-01), Friedman et al.
patent: 6350730 (2002-02-01), Friedman et al.
patent: 6936439 (2005-08-01), Mann et al.
patent: 7112659 (2006-09-01), Mann et al.
patent: 7208577 (2007-04-01), Pelleymounter et al.
patent: 2205572 (1995-12-01), None
patent: 2195955 (1996-02-01), None
patent: 2224646 (1997-01-01), None
patent: 2238307 (1997-07-01), None
patent: 306673 (1989-03-01), None
patent: 401384 (1989-12-01), None
patent: 362999 (1990-04-01), None
patent: 417563 (1991-03-01), None
patent: 464533 (1992-01-01), None
patent: 956862 (2002-12-01), None
patent: WO 89/10932 (1989-11-01), None
patent: WO 91/11111 (1991-08-01), None
patent: WO 92/13559 (1992-08-01), None
patent: WO 94/06476 (1994-03-01), None
patent: WO 96/03141 (1996-02-01), None
patent: WO 96/04388 (1996-02-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/18412 (1996-06-01), None
patent: WO 96/22308 (1996-07-01), None
patent: WO 96/31526 (1996-10-01), None
patent: WO 97/00319 (1997-01-01), None
patent: WO 97/18833 (1997-05-01), None
patent: WO 97/24137 (1997-07-01), None
patent: WO 97/24440 (1997-07-01), None
patent: WO 98/28427 (1998-07-01), None
patent: WO 98/46257 (1998-10-01), None
patent: WO 99/02711 (1999-01-01), None
patent: WO 99/22764 (1999-05-01), None
Verploregen et al, FEBS 405: 237-240, 1997.
Mantzoro et al, Annals of Internal Medicine 130(8): 671-680, Apr. 1999.
Abuchowski, A., et al., “Soluble Polymer-Enzyme Adducts,” Enzymes as Drugs, 1981, 367-383.
Adjei, et al., “Bioavailability of Leuprolide Following Intratracheal Administration to Beagle Dogs,” Int'l Journal of Pharmaceutics, 1990, 135-144, vol. 61.
Adjei, et al., Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate . . . Pharm. Res., 1990, 565-569, vol. 7, No. 6.
Ashkenazi, et al., “Immunoadhesins: An Alternative to Human Monoclonal Antibodies,” Methods, A Companion to Methods in Enzymology, 1995, 104-115, vol. 8.
Ashkenazi, et al., “Protection Against Edotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,” PNAS USA, 1991, 10535-10539, vol. 88.
Attwood, T., et al., “The Babel of Bioinformatics,” Science, Oct. 2000, 471-473, vol. 290 (5491).
Bachmann, et al., “Recalibrated Linkage Map ofEscherichia coliK-12,” Bacteriological Reviews, 1976, 116-167, vol. 40.
Barinaga, M., “Obese Protein Slims Mice,” Science, 1995, 475-476, vol. 269.
Bennett, B., et al., “Estracellular Domaln-IGG Fusion Proteins for Three Human Natruiretic Peptide Receptors,” J. BioChem., 1991, 23060-23067, vol. 266, No. 34.
Braquet, et al., “Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig,” J. Cardiovascular Pharm., 1989, S143-S146, vol. 13 (Supp. 5).
Campfield, L.A., et al., “Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks,” Science, 1995, 54-549, vol. 269.
Capon, D., et al., “Designing CD4 Immunoadhesins for AIDS Therapy,” Nature, Feb. 9, 1989, 525-531, vol. 337.
Debs, et al., “Lung-Specific Delivery of Cytokines Kinduces Sustained Pulmonary and Systemic Immunomodulation in Rats,” J. of Immunology, 1988, 3482-3488, vol. 140, No. 10.
Devos, R., et al., “OB Protein Binds Specifically to the Choroid Plexus of Mice and Rats,” PNAS, USA, May 1996, 5668-5673, vol. 93.
Ellison, et al., “The Nucleotide Sequence of a Human Immunoglobulin Cy1 Gene,” Nucleic Acids Research, 1982, 4071-4079, vol. 10, No. 13.
Fisher, C., et al. “Treatement of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein,” N. Engl. J. Med., 1996, 1697-17022, vol. 334.
Francis, Focus on Growth Factors, 1992, 4-10, vol. 3.
Haak-Frendscho, M., et al., “Inhibition of Interferon-y by an Interferon-y Receptor Immunoadhesin,” Immunology, 1993, 594-599, vol. 79.
Halaas, et al., “Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene,” Science, 1995, 543-546, vol. 269.
Harvey, et al., Remington's Pharmaceutical Sciences, 18th Ed., 1990, 948-1001, Mack Publishing Co., Easton, PA.
Harvill, E., et al., “An IgG3-IL2 Fusion Protein Activates Complement . . . ,” Immunotechnology, 1995, 95-105, vol. 1.
Ho, S.N., et al., “Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction,” Gene, 1989, 51-59, vol. 77.
Hollenbaugh, et al., Current Protocols in Immunology, 1992, Supp., 10.19.1-10.19.11.
Hubbard, et al., “Anti-Neutrophil-Elastase Defenses of the Lower Respiratory Tract . . . ” Annals of Internal Medicine, 1989, 206-212, vol. 111, No. 3.
Imagawa, K., et al., “Structure-Function Studies of Human Leptin,” J. Biological Chem., 1998, 35245-35249, vol. 273, No. 52.
Kolaczynski, J., et al., “Acute and Chronic Effects of Insulin on Leptin Production in Humans: Studies in vivo and in vitro.” Diabetes, 1996, 699-701, vol. 45, No. 5.
Leshner, et al., “A Simple Method for Carcass Analysis,” Physiology and Behavior, 1972, 281-282, vol. 9.
Luoh, S-M., et al., “Cloning and Characterization of a Human Leptin Receptor Using a Biologically Active Letpin Immunoadhesin,” J. Molecular Endo., 1997, 77-85, vol. 18.
MacDonald, et al., “Isolation of RNA Using Guranidinium Salts,” Methods in Enzymology, 1987, 219-227, vol. 152.
Malik, F., et al., “Polyethylen Glycol (PEG)-modified Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) . . . ,” Exp. Hematol. 1992, 1028-1035.
Mark, M., et al., “Expression and Characterization of Hepatocyte Growth Factor Receptor-IgG Fusion Proteins,” J. Bio. Chem., 1992, 26166-26171, vol. 267, No. 36.
Marshall, Modem Pharmaceutics, 1979, 359-427, Marcel Dekker, Inc., NY.
Mikayama, T., et al., “Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor,” PNAS, USA, 10056-10060, vol. 90.
Murakami, T., et al., “Cloning of a Rat Obese cDNA and Its Expression in Obese Rats,” Biochem. Biophys. Res. Comm., 1995, 944-952, vol. 209, No. 3.
Newmark, et al., “Preparation and Properties of Adducts of Streptokinase and Streptokinase-Plasmin Complex . . . ” J. Appl. Biochem., 1982, 185-189. vol. 4.
Ngo, et al., The Protein Folding Problem and Tertiary Structure Prediction, 491-495.
Oeswein, et al., “Aerosolization of Proteins,” Proceddings of Symposium on Respiratory Dtrug Delivery II, Mar. 1990, Keystone, CO.
Pelleymounter, M.A., et al.,

Affiliated with

Also associated with

Rating

OB fusion protein compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with OB fusion protein compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and OB fusion protein compositions and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4308792